Join Growin Stock Community!

Compugen ltd.CGEN.US Overview

US StockHealthcare
(No presentation for CGEN)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

CGEN AI Insights

CGEN Overall Performance

CGEN AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

CGEN Recent Performance

23.12%

Compugen ltd.

0.05%

Avg of Sector

-0.31%

S&P500

CGEN PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

CGEN Key Information

CGEN Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

CGEN Profile

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I clinical study in patients with advanced malignancies as a monotherapy; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with solid tumors; and AZD2936, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase I/II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused primarily on myeloid targets. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.

Price of CGEN

CGEN FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.30
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
24.68
PB Ratio
3.80
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
7.43%
Net Margin
-400.10%
Revenue Growth (YoY)
-88.47%
Profit Growth (YoY)
-98.99%
3-Year Revenue Growth
-12.16%
3-Year Profit Growth
-31.85%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.30
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
24.68
PB Ratio
3.80
Price-to-FCF
-
Gross Margin
7.43%
Net Margin
-400.10%
Revenue Growth (YoY)
-88.47%
Profit Growth (YoY)
-98.99%
3-Year Revenue Growth
-12.16%
3-Year Profit Growth
-31.85%

  • When is CGEN's latest earnings report released?

    The most recent financial report for Compugen ltd. (CGEN) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating CGEN's short-term business performance and financial health. For the latest updates on CGEN's earnings releases, visit this page regularly.

  • What is the operating profit of CGEN?

    According to the latest financial report, Compugen ltd. (CGEN) reported an Operating Profit of -7.89M with an Operating Margin of -417.4% this period, representing a decline of 275.56% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is CGEN's revenue growth?

    In the latest financial report, Compugen ltd. (CGEN) announced revenue of 1.89M, with a Year-Over-Year growth rate of -88.96%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does CGEN have?

    As of the end of the reporting period, Compugen ltd. (CGEN) had total debt of 2.95M, with a debt ratio of 0.03. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does CGEN have?

    At the end of the period, Compugen ltd. (CGEN) held Total Cash and Cash Equivalents of 59.36M, accounting for 0.61 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does CGEN go with three margins increasing?

    In the latest report, Compugen ltd. (CGEN) did not achieve the “three margins increasing” benchmark, with a gross margin of 12.7%%, operating margin of -417.4%%, and net margin of -369.1%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess CGEN's profit trajectory and future growth potential.

  • Is CGEN's EPS continuing to grow?

    According to the past four quarterly reports, Compugen ltd. (CGEN)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.07. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

CGEN Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1